HepaStem: toward an alternative to liver transplantation

Promethera Biosciences’ HepaStem platform offers the first allogeneic off-the-shelf, liver-derived stem cell therapy for severe liver diseases that could become an alternative to liver transplantation.

Like Comment
Page of
Go to the profile of Promethera


Promethera Biosciences is a global innovator in liver therapeutics whose mission is to enable patients to overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

No comments yet.